From ‘One-Size-Fits-All’ to ‘Tailored Solutions’: ADC+IO Combination Breaks the Treatment Dilemma of MIBC
Key Points 1 For patients with muscle-invasive bladder cancer (MIBC) who are not suitable for cisplatin treatment, sacituzumab govitecan and pembrolizumab show promise as alternatives to radical cystectomy, with a clinical complete response rate (cCR) of 44.4%. 2 The SURE-02 trial emphasizes bladder preservation, adjusting treatment plans based on patient preferences and treatment responses, shifting … Read more